Cancer – ADVL1622: Phase 2 Trial of XL154 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor and Other Rare Tumors
Condition or Therapy:
Carcinomas, Wilms tumors
Cancer and Blood Disorders
Study Number: ADVL1622
What is the goal of this study?
Researchers want to determine the response rate of cabozantinib-s-malate in patients who have sarcomas.
Who can join the study?
This study may be a good fit for children and young adults who:
- are 2 to 30 years old, and
- have been diagnosed or newly diagnosed with recurrent, refractory Ewing sarcoma, rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcomas (STS), osteosarcoma, Wilms tumor or rare tumors.
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.